Joseph Monahan, Chief Scientific Officer at Aclaris Therapeutics, Inc. (ACRS), sold 6,000 shares at $5.08 ($30K) on 2023-10-23, disclosed to the SEC on 2023-10-25.
Scheduled sale ($30k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ACRS | SELL | 2023-03-03 | $588K | — | Filing → |
| ACRS | SELL | 2023-02-17 | $65K | — | Filing → |
| ACRS | SELL | 2022-12-16 | $79K | — | Filing → |